Ceftazidime/Avibactam versus Polymyxin B in the Challenge of Carbapenem-Resistant Pseudomonas aeruginosa Infection.
Juan ChenQiqiang LiangXinyi ChenJing WuYanchao WuGaoqin TengMan HuangPublished in: Infection and drug resistance (2022)
CAZ/AVI therapy was superior to polymyxin B therapy for patients with CRPA infection, and provided significant survival benefits, but further larger studies were needed to substantiate our findings.